Literature DB >> 8818545

Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor.

R Eliaz1, D Wallach, J Kost.   

Abstract

Chronic inflammatory diseases are associated with increased soluble tumour necrosis factor (TNF) receptor concentrations in serum. To obtain such an increase, we implanted mice with ethylene vinyl-acetate or poly (lactic-co-glycolic) acid copolymers containing human soluble p55 TNF receptor. Copolymers containing rather small amounts of the receptor (about 20 micrograms) maintained prolonged increases in serum receptor concentrations. Mice implanted with these copolymers were effectively protected against lethal wasting and from arthritis resulting from chronic exposure to TNF. These findings suggest that the increased production of soluble TNF receptors in chronic inflammatory diseases counteracts deleterious effects of TNF, and suggest a therapeutic application for the natural forms of the receptors in such diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818545     DOI: 10.1006/cyto.1996.0065

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo.

Authors:  R E Eliaz; D Wallach; J Kost
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 2.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

3.  Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis.

Authors:  L Armstrong; N M Foley; A B Millar
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

4.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.